What one share of Zeo Scientifix holds
We are a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and regenerative medicine.
Zeo Scientifix’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-04-30; the balance sheet is as of 2026-06-30.
| Sales | $1.01 |
|---|---|
| Profit | −$0.56 |
| Cash and investments | $0.29 |
| Book value | $0.07 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $1.14 | −$1.56 | $0.14 | −$0.70 | — | $0.26 |
| 2023 | $0.65 | −$0.99 | $0.00 | −$0.32 | — | −$0.17 |
| 2024 | $0.73 | −$0.74 | — | — | — | −$0.26 |
| 2025 | $0.81 | −$0.86 | $0.00 | −$0.12 | — | −$0.21 |
Common questions about Zeo Scientifix
How much does one share of Zeo Scientifix earn?
Over the last 12 months, Zeo Scientifix lost $0.56 for each share on $1.01 of sales.
Does Zeo Scientifix pay a dividend?
Zeo Scientifix didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Zeo Scientifix’s book value per share?
Zeo Scientifix’s book value is $0.07 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Zeo Scientifix have?
Each share of Zeo Scientifix has $0.29 of cash and investments, as of June 30, 2026.
Has Zeo Scientifix bought back shares?
Zeo Scientifix’s share count rose about 13% from 2022 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.